Home » Grants » Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant (USA)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant (USA)

The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant from Pfizer supports researchers in the USA working on ATTR Amyloidosis. Applicants must be based at a research institution and must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.

The grant seeks to fund projects on:

  • Approaches for the early identification and follow up of ATTR amyloidosis patients
  • Real-world (RW) efficacy and safety of tafamidis in the clinical setting for the management of
  • ATTR amyloidosis
  • Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy
  • and polyneuropathy)
  • Gender/sex-related differentiation
  • Pathophysiology

Applicants may apply for up to 75,000 USD/year in funding support (including up to 28% of overheads) for 1-2 years.

Applications close on April 27, 2023.

Challenge: Rare Diseases

Sign in with your free account to see important eligibility criteria, including research location, citizenship, legal working rights and deadline/s.

Sign-up for the
monthly research
funding newsletter

You can unsubscribe at any time.